Monoclonal Gammopathy of Undetermined Significance is Not Associated with Renal Cell Carcinoma
Deniz Yılmaz1, Ezgi Şahin2, Emine Gültürk3, Serdar Karadağ41Department of Internal Diseases, University of Health Sciences Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Türkiye2Department of Rheumatology, Istanbul University Faculty of Medicine, Istanbul, Türkiye
3Department of Hematology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Türkiye
4Department of Urology, Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Türkiye
Objectives: The aim of this study was to investigate monoclonal gammopathy of undetermined significance (MGUS) in patients with renal cell carcinoma (RCC) and compare to healthy individuals.
Methods: This was a case-control study conducted between July 2022 and December 2022 including 68 patients with RCC and 47 healthy controls.
Results: The median age of control group was 67 (51-75) years and that of the RCC group was 59 (51-69.5) (p=0.039). Sex distributions were similar in the two groups. RCC disease duration was 24 (12-60) months. The albumin, calcium, hemoglobin, hematocrit levels, and lymphocyte (p<0.001 for all) and platelet counts (p=0.017) were significantly higher in the RCC group compared to controls. There was no significant difference between the groups in terms of the number of the patients with MGUS (p=0.512), monoclonal band positivity (p=0.512), abnormal bands positivity (p=0.080) and median gammaglobulin level (p=0.774).
Conclusion: The present study shows no evidence for increased MGUS incidence in patients with RCC; however, more comprehensive studies are required to clarify these findings in different populations and determine the potential roles of other factors in the relationship between RCC and MGUS.
Manuscript Language: English
